Welcome to the EPA 2022 Interactive Programme 

The congress will officially run on Central European Summer Time (CEST/GMT +2) 

To convert the congress times to your local time Click Here 

Icon

Description automatically generatedFully Live with Live Q&A Icon

Description automatically generatedOn Demand (available from 4 June)  Icon

Description automatically generatedECP Session 

Icon

Description automatically generatedSection Session Icon

Description automatically generatedEPA Course (Pre-Registration Required)   Ask the Expert

Displaying One Session

Session Type
Industry
Date
Sun, 05.06.2022
Session Time
13:00 - 13:30
Room
Product Theatre
Session Description
Cariprazine dosing recommendations for the treatment of schizophrenia-Supported by Gedeon Richter and Recordati.

Session Description:

Antipsychotic dosing plays a crucial role in the long-term care of patients with schizophrenia, however, finding the optimal dose is not always straightforward. In case of cariprazine, evidence on the dosing and titration of the compound mainly comes from randomised controlled trials. Despite such trials being the gold standard, real-world evidence needs to be gathered as well in order to draw accurate conclusions on dosing. Therefore, by presenting both clinical and real-world evidence, this session aims to provide a comprehensive picture on the appropriate dosing strategies of cariprazine, including treatment initiation, switching strategies and concomitant medications.

Cariprazine dosing recommendations for the treatment of schizophrenia

Session Type
Industry
Date
Sun, 05.06.2022
Session Time
13:00 - 13:30
Room
Product Theatre
Lecture Time
13:00 - 13:30